30 July 2024
Scancell Holdings
plc
("Scancell" or the "Company")
Scancell Provides Update from
iSCIB1+ Clinical Advisory Meeting to Strengthen Plans for Phase 2/3
Registration Clinical Trial
A panel of international key
opinion leaders in the treatment of Melanoma convened in Chicago to
offer strategic guidance in the design of Scancell's Phase 2/3
seamless adaptive registration study.
The SCIB1 stage 1 clinical
data poster was very well received at ASCO.
Scancell Holdings plc (AIM: SCLP),
the developer of novel immunotherapies for the treatment of cancer,
today announces that a group of leading medical oncologists in the
field of melanoma treatment reviewed and strengthened Scancell's
plan for a Phase 2/3 registration study following completion of the
ongoing SCOPE study.
Scancell's plans to conduct an
adaptive randomised controlled Phase 2/3 SCOPE-2 trial is supported
by a panel of experts. The study is expected to have an early
interim analysis of Overall Response Rate (ORR) based on a blinded
independent centralised review of CT/MRI scans before advancing to
the Phase 3 component where the primary endpoint of
progression-free survival will be analysed at a predetermined
landmark.
The panel comprised the following
members:
|
Name
|
Institution
|
|
Paul Chapman
|
Weill Cornell Medicine and
NewYork-Presbyterian, New York, NY, USA
|
|
Pippa Corrie
|
Cambridge Cancer Centre,
Addenbrooke's Hospital, Cambridge, UK
|
|
Alexander Eggermont
|
Princess Máxima Center for Pediatric
Oncology, Utrecht, Netherlands.
|
|
Georgina Long
|
Melanoma Institute Australia,
Sydney, Australia.
|
|
Sapna Patel
|
University of Colorado Cancer
Center, USA
|
|
Michael Postow
|
Memorial Sloan Kettering Cancer
Center, New York, NY, USA
|
|
Heather Shaw
|
University College Hospital, London,
UK
|
|
Jeffrey Weber
|
Pelmutter Cancer Center, New York,
NY, USA
|
|
Jedd Wolchok
|
Weill Cornell Medicine and
NewYork-Presbyterian, New York, NY, USA
|
A poster, presenting the first stage
of the SCOPE study, was also very well received at ASCO with Prof
Durrant, Dr Heather Shaw, Dr Robert Miller and Mr Fayaz Master
discussing the results for three hours with oncologists,
pharmaceutical companies and commercial enterprises.
Scancell continues to recruit to the
SCOPE study, which includes patients treated with SCIB1 as well as
iSCIB1+. 32/43 patients have been recruited into the SCIB1
cohort and 22/43 into the iSCIB1+ cohort, with clinical results
expected in Q4 2024 and Q1 2025, respectively.
Prof Lindy Durrant, Chief Executive Officer, Scancell
said: "We are very grateful to the
esteemed panel for their interest in our SCOPE results and their
input into our further clinical study. The panel felt that the data
was compelling enough to proceed to the Phase 2/3 randomised
registration study upon the completion of the SCOPE study. We were
also overwhelmed by the interest in the poster, which is the most
significant response I have seen in my career."
Dr. Wolchok serves as an
uncompensated consultant for Scancell Limited.
Dr. Chapman serves as a compensated
consultant for Scancell Limited.
-ENDS-
|
For
further information, please contact:
|
|
|
|
|
|
Scancell Holdings plc
|
+44 (0) 20 3709 5700
|
|
Dr Jean-Michel Cosséry,
Non-Executive Chairman
|
|
|
Professor Lindy Durrant,
CEO
|
|
|
|
|
|
Panmure Liberum Limited (Nominated Advisor and Joint Broker)
|
+44 (0) 20 7886 2500
|
|
Emma Earl, Freddy Crossley, Will
Goode, Mark Rogers (Corporate Finance)
|
|
|
Rupert Dearden (Corporate
Broking)
|
|
|
WG
Partners LLP (Joint
Broker)
David Wilson/Claes Spang/Satheesh
Nadarajah/Erland Sternby
|
+44 (0) 20 3705 9330
|
|
|
|
ICR
Consilium
|
+44 (0) 20 3709 5700
|
|
Mary-Jane Elliott/Angela
Gray/Lindsey Neville
|
scancell@consilium-comms.com
|
About Scancell
Scancell is a clinical stage
biopharmaceutical company that is leveraging its proprietary
research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant
unmet needs in cancer. The Company is building a pipeline of
innovative products by utilising its four technology platforms:
Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab®
for antibodies.
Adaptive immune responses include
antibodies and T cells (CD4 and CD8), both of which can recognise
damaged or infected cells. In order to destroy such cancerous or
infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells
or drugs. The Company's unique approach is that its innovative
products target modifications of proteins and lipids. For the
vaccines (Moditope® and ImmunoBody®) this includes citrullination
and homocitrullination of proteins, whereas its mAb portfolio
targets glycans or sugars that are added onto proteins and / or
lipids (GlyMab®) or enhances the potency of antibodies and their
ability to directly kill tumour cells (AvidiMab®).
For further information about
Scancell, please visit: https://www.scancell.co.uk/